Please note that the contents in this webpage are current as of the date of the announcement and the information including but not limited to the product availability, specification, prices, contacts, are subject to change without prior notice.
- Apr 16, 2024
- FUJIFILM Toyama Chemical and Synplogen Enter Strategic Business Alliance Agreement on CDMO Services for mRNA therapeutics, to Provide Seamless End-to-End Services from mRNA Sequence Design to LNP Formulation and Fill/Finish
- Feb 5, 2024
- TriLink BioTechnologies® and FUJIFILM Toyama Chemical Sign Non-exclusive License and Supply Agreement for CleanCap® mRNA capping technology
- Oct 14, 2022
- FUJIFILM Toyama Chemical discontinues development of “Avigan® Tablet” anti-influenza drug as a treatment for COVID-19 (Fujifilm)
- Oct 6, 2022
- Fujifilm to establish its first Bio-CDMO site in Japan (Fujifilm)
- Mar 22, 2022
-
Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business
Amendment in relation to a return of domestic marketing rights for a product (Fujifilm) - Mar 11, 2022
- Fujifilm to terminate the enrollment of subjects in the phase III clinical trial of anti-influenza drug Avigan® Tablet in Japan, targeting COVID-19 patients (Fujifilm)